Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Eli Lilly and : Lilly Study Looks at Migraine Treatment Patterns

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 08:45am EDT

By Michael Dabaie

Eli Lilly and Co. (LLY) said study data highlighted inconsistent and sub-optimal treatment patterns that people living with migraine experience.

The study collected responses from more than 20,000 people living with migraine. The results showed people with migraine seek care in a variety of settings, with a significant portion seeking treatment in emergency department and urgent care settings, Lilly said.

Among respondents with four or more migraine headache days per month, more than 60% reported seeking care during the last 12 months. Of this, 33.6% sought care for migraine at an emergency department or urgent care clinic. Less than 5% of people seeking care at emergency departments, urgent care or retail clinics were prescribed migraine preventive medication, Lilly said.

The study authors recommend more research to understand whether improving consistency in migraine care, and appropriately treating people in a specialist or primary care setting, improves patient outcomes and reduces the need for emergency or urgent care, Lilly said.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.50% 96.83 Delayed Quote.-2.68%
ELI LILLY AND COMPANY -1.43% 106.79 Delayed Quote.-6.38%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
10:44aELI LILLY AND : Acacia Pharma Group plc - Founder Dr. Julian Gilbert steps down ..
AQ
07/18ELI LILLY AND : AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau..
AQ
07/17AC Immune, Lilly Begin Dosing Subject with Tau Morphomer Inhibitor
DJ
07/15ELI LILLY AND COMPANY : - AHS 2019 Post-Hoc Analyses of Phase 3 Pivotal Studies ..
AQ
07/15ELI LILLY AND : Lilly's OVERCOME Observational Study Reveals Inconsistent and Su..
AQ
07/15ELI LILLY AND : Lilly Presents New Findings on Stigma Faced by People with Migra..
AQ
07/13ELI LILLY AND : Lilly Presents New Findings on Stigma Faced by People with Migra..
PU
07/12ELI LILLY AND COMPANY : - New England Journal of Medicine Publishes Positive Pha..
AQ
07/12ELI LILLY AND : Lilly Study Looks at Migraine Treatment Patterns
DJ
07/12ELI LILLY AND : Lilly's OVERCOME Observational Study Reveals Inconsistent and Su..
PU
More news
Financials (USD)
Sales 2019 22 171 M
EBIT 2019 6 243 M
Net income 2019 8 126 M
Debt 2019 3 031 M
Yield 2019 2,36%
P/E ratio 2019 12,1x
P/E ratio 2020 17,4x
EV / Sales2019 4,57x
EV / Sales2020 4,48x
Capitalization 98 336 M
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 126,70  $
Last Close Price 106,79  $
Spread / Highest target 35,8%
Spread / Average Target 18,6%
Spread / Lowest Target -12,9%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Michael R. Meadows VP & Chief Technology Officer
Aarti Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-6.38%99 763
JOHNSON & JOHNSON2.18%350 653
PFIZER-2.08%239 061
ROCHE HOLDING LTD.11.42%234 924
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699